Physician profile
William N Katkov
NPI 1386693646
$3,356.98
in general payments reported to CMS, 2019-2025
24 companies · $783 in 2025
The $783 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $111 · 2021: $233 · 2022: $434 · 2023: $481 · 2024: $950 · 2025: $783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,192.22 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.80 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $553.99 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $341.19 | 2021-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $184.31 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $175.27 | 2019-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $162.03 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $132.14 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $119.50 | 2019-2022 | |
| Intuitive Surgical, INC. | $105.74 | 2022 | |
| Merck Sharp & Dohme LLC | $81.23 | 2019-2024 | |
| Pfizer INC. | $77.05 | 2023-2024 | |
| Lilly USA, LLC | $73.29 | 2024-2025 | Omvoh |
| Genzyme Corporation | $66.09 | 2022-2023 | |
| Braintree Laboratories, INC. | $62.09 | 2020-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $53.91 | 2024 | Bylvay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $45.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $44.89 | 2019-2023 | Rebyota |
| Lucid Diagnostics INC. | $35.95 | 2022 | |
| Exact Sciences Corporation | $27.94 | 2025 | Cologuard Collection Kit |
| Shionogi INC | $20.80 | 2019 | |
| Aimmune Therapeutics, INC. | $19.59 | 2024 | |
| Celltrion USA INC. | $17.91 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $17.47 | 2024 | |
| Echosens North America, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Katkov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.